Evidence map›Paper›PMID 28781817›Full record

ArticleMolecular and clinical oncology2017

Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population.

Shiirevnyamba Avirmed, Bo-Shen Wang, Baasansuren Selenge, Amarsaikhan Sanjaajamts, Batmunkh Ganbat, Ulziisaikhan Erdenebileg, Myagmarsuren Purevsuren, Sarantsetseg Jigjidsuren, Munkhbat Batmunkh, Yi-Jang Lee

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The frequency ofInternational journal of reproductive biomedicine · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Shiirevnyamba AvirmedDivision of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Bo-Shen WangDepartment of Biomedical Imaging and Radiological Sciences, School of Biomedical Engineering, National Yang-Ming University, Taipei 112, Taiwan.
Baasansuren SelengeDivision of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Amarsaikhan SanjaajamtsDivision of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Batmunkh GanbatDivision of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Ulziisaikhan ErdenebilegDivision of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Myagmarsuren PurevsurenDivision of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Sarantsetseg JigjidsurenDepartment of Clinical Laboratory, First Central Hospital of Mongolia, Ulaanbaatar 210648, Mongolia.
Munkhbat BatmunkhScience Technology Center, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Yi-Jang LeeDepartment of Biomedical Imaging and Radiological Sciences, School of Biomedical Engineering, National Yang-Ming University, Taipei 112, Taiwan.
Mongolian National University of Medical Sciences · MNMongolian National University · MNNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aims to investigate whether MDM2-SNP309 and p53R72P polymorphisms were associated with the risk of bladder cancer in Mongolian populations. These polymorphisms were evaluated in 79 controls and 63 bladder cancer cases using a PCR-restriction fragment length polymorphism assay, followed by analysis using multivariate logistic regression model and the Kaplan-Meier model to determine the odds ratio (OR) and age at onset of bladder cancer, respectively. The results revealed that the homozygous (G/G) genotype of MDM2-SNP309 increased the risk of bladder cancer compared to the wild-type (T/T) genotype [OR=1.629; 95% confidence interval (CI)=0.622-4.266] among Mongolians. On the other hand, the homozygous (P/P) genotype of p53R72P tended to protect the population from bladder cancer compared with the wild-type (R/R) genotype (OR=0.445; 95% CI=0.1727-2.147). It also showed that G/G genotype of MDM2-SNP309 increased the risk of bladder cancer when combined with the R/R genotype of p53R72P (OR=3.355; 95% CI=0.3914-28.766). Stratification by smoking and history of chronic urinary tract diseases tended towards increasing the risk association of the G/G (OR=2.3704; 95% CI=0.4308-3.044) and T/G genotypes (OR=5; 95% CI=0.8442-30.4088) of MDM2-SNP309 with bladder cancer, respectively. The protective role of P/P of p53R72P remained following stratification. MDM2-SNP309 and p53R72P were not involved in early age onset of bladder cancer in Mongolian patients. Taken together, MDM2-SNP309 and p53R72P had no significant association with bladder cancer in Mongolian patients. The two SNPs were also not able to predict early age at onset of bladder cancer.

Indexed as

bladder cancerMDM2-SNP309Mongolian patientsp53R72Prisk association

Identifiers

PMID28781817
PMCPMC5530310
OpenAlexW2735486882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.